Analyst Price Target is $14.25
▲ +81.30% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Jounce Therapeutics in the last 3 months. The average price target is $14.25, with a high forecast of $17.00 and a low forecast of $10.00. The average price target represents a 81.30% upside from the last price of $7.86.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in Jounce Therapeutics. This rating has held steady since January 2021, when it changed from a Hold consensus rating.
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.